Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.

@article{Montillo2003PhaseIS,
  title={Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.},
  author={Marco Montillo and Alessandra Tedeschi and Susan O'brien and Francesco Di Raimondo and Susan Lerner and Alessandra Ferrajoli and Enrica Morra and Michael J Keating},
  journal={Cancer},
  year={2003},
  volume={97 1},
  pages={
          114-20
        }
}
BACKGROUND One of the mechanisms of action of cladribine is the inhibition of DNA repair of damage caused by radiation, alkylating agents, or other drugs. To determine its antitumor activity in combination with cyclophosphamide, we initiated a Phase II trial of the two agents in patients with advanced chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL). METHODS Twenty-nine patients with refractory or recurrent CLL or PLL received cladribine 4 mg/m(2)/day and cyclophosphamide… CONTINUE READING
Highly Cited
This paper has 34 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Chronic lymphocytic leukemia: diagnosis and treatment.

Mayo Clinic proceedings • 2006
View 6 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 42 references

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2001
View 2 Excerpts

Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology • 1999
View 1 Excerpt

Clinical challenges in chronic lymphocytic leukemia.

Seminars in hematology • 1998
View 3 Excerpts